Purity Alogliptin Intermediate Material Alogliptin Benzoate Powder Pharmaceutical Chemical Alogliptin

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Alogliptin
• Product Name: Alogliptin
• Name: Alogliptin Powder
• Appearance: White or off White Solid Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antidiabetic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 850649-61-5
• Mf: C18h21n5o2
• MW: 339.397
• Density: 1.342
• Boiling Point: 519.238 C at 760 Mmhg
• Refractive Index: 1.660
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 2 Ton/Month

Product Description

Purity Alogliptin Intermediate Material Alogliptin Benzoate Powder Pharmaceutical Chemical Alogliptin

 

Product Description

Product Details

Product Name	Alogliptin
CAS No.	850649-61-5
MF	C18H21N5O2
MW	339.397
Appearance and shape	White or off white solid powder

Alogliptin benzoate is a serine protease two peptide peptidase IV (DPP- IV) inhibitor developed.  This product can maintain the levels of glucagon like peptide 1 (GLP-1) and Glucose dependent insuli n-like growth polypeptide (GIP) in vivo and promote the secretion of insuli n and thus exert hypoglycemic effect. A randomized, placebo-controlled clinical trial results showed that, compared with placebo Agger gliptin monotherapy can significantly improve glycemic control in type 2 diabetes, did not increase the incidence of hypoglycemia,well tolerated. A Glenn Dean and the medicine composition is the sitagliptin, vildagliptin asked the city after oral administration of effective specific DPP- IV inhibitors, provides a new choice of treatment for patients with type 2 diabetes, and has wide application prospect.

Application & Function

Alogliptin, used alone or in combination with other blood sugar-lowering medication, is usually well-tolerated in type-2 diabetes patients.     This medication has a low risk of hypoglycemia, with Alogliptin treatment groups ≤8.3% and placebo groups ≤10.5%, and shows no difference between young and elderly patients.In addition to effectively lowering blood sugar, this medicine also lowers the risks of hypoglycemia and weight increase, overcoming great obstacles in patient treatment and providing new hope for diabetes treatment.

Specification